AR and prostate carcinoma: As mentioned above, the p300/CBP reader bromodomain inhibitor CCS1477 is currently in early-phase clinical trials; given this, we tested CCS1477 and another reader bromodomain inhibitor, GNE-049, for their ability to attenuate p300/CBP activity in AR-positive prostate cancer cells17,21.